Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR2 | Q8NFJ6 | 5/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL565356 | 0.92 | PROKR2 (0.47) | PROKR2KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL565439 | 0.89 | PROKR2 (0.67) | PROKR2S1PR1KDM4EALDH1A1HPGD | |
| SCHEMBL565355 | 0.89 | PROKR2 (0.42) | PROKR2KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL10107480 | 0.88 | PROKR2 (0.58) | PROKR2MEN1KMT2A | |
| SCHEMBL10107414 | 0.86 | PROKR2 (0.55) | PROKR2ALDH1A1SMN1; SMN2MEN1HTT | |
| SCHEMBL13284334 | 0.82 | PROKR2 (0.57) | PROKR2KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL565040 | 0.82 | PROKR2 (0.52) | PROKR2 | |
| SCHEMBL565461 | 0.82 | PROKR2 (0.59) | PROKR2MAPK1 | |
| SCHEMBL565544 | 0.82 | PROKR2 (0.62) | PROKR2KMT2A | |
| SCHEMBL565027 | 0.82 | PROKR2 (0.55) | PROKR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722896-B2 | Prokineticin receptor antagonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722896-B2 | Prokineticin receptor antagonists and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035149-A1 | Prokineticin Receptor Antagonists And Uses Thereof | PROKR2, PROKR1, GIPR | PROKR2 1/4885S1PR1 1759/4885KDM4E 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.